Anzeige
Meldung des Tages: Wegweisende News: NurExone – Pionier der regenerativen neuronalen Medizin!

Lipocine News

Aktie
WKN:  A3EBZD ISIN:  US53630X2036 US-Symbol:  LPCN Land:  USA
9,65 $
-0,04 $
-0,41%
8,1653 € 27.02.26
Depot/Watchlist
Marktkapitalisierung *
23,77 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Lipocine News

18.02.26 - PR Newswire
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) PR Newswire
20.01.26 - PR Newswire
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire
12.01.26 - PR Newswire
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire
16.12.25 - PR Newswire
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone PR Newswire
18.11.25 - PR Newswire
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire
06.11.25 - PR Newswire
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 PR Newswire
04.11.25 - PR Newswire
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® PR Newswire
30.09.25 - PR Newswire
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) PR Newswire
05.09.25 - PR Newswire
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
26.08.25 - PR Newswire
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 PR Newswire
05.08.25 - PR Newswire
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 PR Newswire
26.06.25 - PR Newswire
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression PR Newswire
23.06.25 - PR Newswire
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 PR Newswire
09.06.25 - PR Newswire
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada PR Newswire
22.05.25 - PR Newswire
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology PR Newswire
14.05.25 - PR Newswire
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase PR Newswire
08.05.25 - PR Newswire
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 PR Newswire
26.03.25 - PR Newswire
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 PR Newswire
13.03.25 - PR Newswire
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 PR Newswire
12.03.25 - PR Newswire
Lipocine Announces FDA Labeling Changes for Testosterone Products
Lipocine Announces FDA Labeling Changes for Testosterone Products PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »